30 March 2026
Swissmedic: Mandatory Registration of MD-DEVIT Products in swissdamed from July 2026
From 1 July 2026, registration of MD-DEVIT products containing devitalised human tissue in swissdamed becomes mandatory, replacing previous notification requirements, with a transition period until 31 December 2026. For certain DEVIT products regulated under older law, the notification obligation remains until a new specific ordinance is introduced.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting